SETD4 Confers Cancer Stem Cell Chemoresistance in Nonsmall Cell Lung Cancer Patients via the Epigenetic Regulation of Cellular Quiescence

Table 2

Clinicopathological features of 42 NSCLC patients who received platinum-based combination chemotherapy.

Characteristics	Response evaluation
	Resistant ()	Sensitive ()
Age (years)
Median (range), y	66 (52-73)	63 (35-75)
Sex
Male	20	17
Female	1	4
Stage
IIIB, IIIC	5	8
IV	16	13
Histology
Adenocarcinoma	6	10
Squamous carcinoma	14	11
Adenosquamous carcinoma	1	0
Chemotherapy regimens
TAX+platinum	8	3
PEM+platinum	6	10
GEM+platinum	6	8
DTX+platinum	1	0

NSCLC: nonsmall cell lung cancer. TAX: taxol. PEM: pemetrexed. GEM: gemcitabine. DTX: docetaxel. Platinum: cisplatin or carboplatin.